New study tracks safety of popular Crohn's and colitis drugs over time

NCT ID NCT04372108

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the long-term safety of the drug ustekinumab compared to other biologic treatments in adults with Crohn's disease or ulcerative colitis. Researchers will use health records from the Department of Defense to track rates of cancer, serious infections, and other risks. About 1,056 participants who are new users of these drugs will be followed to see how safe they are over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • NMCP

    RECRUITING

    Portsmouth, Virginia, 23708, United States